AMGEN INC
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
AMGN$465.230.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
| Six months endedJune 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income | $3,162 | $633 |
| Noncash adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, amortization and other | 2,728 | 2,799 |
| Impairment of intangible assets | 800 | 68 |
| Stock-based compensation expense | 242 | 260 |
| Deferred income taxes | (672) | (784) |
| (Gains) losses on equity securities | (741) | 916 |
| Other items, net | (73) | (174) |
| Changes in operating assets and liabilities, net of acquisitions: | ||
| Trade receivables, net | (1,823) | 310 |
| Inventories | 527 | 1,528 |
| Other assets | (407) | (339) |
| Accounts payable | 1,086 | 666 |
| Accrued income taxes, net | (2,313) | (1,311) |
| Long-term tax liabilities | 162 | (637) |
| Accrued liabilities | (50) | (361) |
| Accrued sales incentives and allowance | 1,113 | (393) |
| Other liabilities | (70) | (33) |
| Net cash provided by operating activities | 3,671 | 3,148 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (780) | (468) |
| Other | (56) | 34 |
| Net cash used in investing activities | (836) | (434) |
| Cash flows from financing activities: | ||
| Extinguishment of debt | (602) | (410) |
| Repayment of debt | (3,500) | (1,400) |
| Dividends paid | (2,559) | (2,417) |
| Other | (119) | (130) |
| Net cash used in financing activities | (6,780) | (4,357) |
| Decrease in cash and cash equivalents | (3,945) | (1,643) |
| Cash and cash equivalents at beginning of period | 11,973 | 10,944 |
| Cash and cash equivalents at end of period | $8,028 | $9,301 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.